Edgewise Therapeutics, Inc. EWTX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Edgewise Therapeutics, Inc. (EWTX) reported accretion (amortization) of discounts and premiums, investments of $1.01M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 47.3% year-over-year, from $1.92M to $1.01M.
- What is the long-term trend for Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 3 years (2022 to 2025), Edgewise Therapeutics, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 141.7% compound annual growth rate (CAGR), from $543K to $7.67M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric represents the non-cash adjustments to the carrying value of investment securities resulting from the amortization of premiums or the accretion of discounts. It reflects the systematic allocation of the difference between the purchase price and the face value of debt securities over their remaining term. Investors use this to understand the non-cash impact of investment portfolio accounting on reported operating cash flows.